- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01729793
Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal
November 26, 2012 updated by: National Enzyme Company
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal
The primary objective of the study is to assess the efficacy of Digestive Enzyme Blend #2, a digestive enzyme dietary supplement product, on markers indicative of inflammation after a meal.
The markers will be assessed by blood levels tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and high sensitivity C-reactive protein (hsCRP) at times 0, 45 minutes, 2 hours and 4 hours post-meal.
A full complete blood count (CBC)and an erythrocyte sedimentation rate (ESR) blood test will also be conducted at times 0 and 4 hours post-meal.
In addition, a questionaire on Gastrointestinal symptoms will be administered 4 hours post-meal.
The study hypothesis is that some or all of these potential markers of inflammation will increase following the meal, and the amount of increase in inflammation will be attenuated when a digestive enzyme is consumed with the meal compared to the placebo.
In addition, it is hypothesized that levels of gastric discomfort as assessed by the questionaire will be reduced with the digestive enzyme compared to the placebo.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to assess the efficacy of Digestive Enzyme Blend #2, a digestive enzyme dietary supplement product, on markers indicative of inflammation after a meal.
The study design is a randomized, double-blind, placebo-controlled, cross-over type study.
The markers will be assessed by blood levels TNF-alpha, IL-1beta, IL-6, and hsCRP at times 0, 45 minutes, 2 hours and 4 hours post-meal.
A full blood CBC panel and an ESR blood test will also be conducted at times 0 and 4 hours post-meal.
In addition, a questionaire on Gastrointestinal symptoms will be administered 4 hours post-meal.
The study hypothesis is that some or all of these potential markers of inflammation will increase following the meal, and the amount of increase in inflammation will be attenuated when a digestive enzyme is consumed with the meal compared to the placebo.
In addition, it is hypothesized that levels of gastric discomfort as assessed by the questionaire will be reduced with the digestive enzyme compared to the placebo.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Synergize Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- If female, not of child bearing potential. Defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgical with >1 year since last menstruation). OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
- Healthy as determined by laboratory results, medical history and physical exam
- Agrees to comply with study protocols
- Has given voluntary, written, informed consent to participate in the study -
Exclusion Criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial.
- Gastrointestinal lesions/ulcer, diabetes, or any condition requiring the use of prescribed medications for treatment
- Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
- History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable.
- History of bleeding disorders, or significant blood loss in the past 3 months
- Use of blood thinning medications.
- Use of anti-inflammatory medications, including over-the-counter pain relievers within the past 14 days.
- Use of prescription medication (other than birth control), vitamins, minerals or other natural health products within the past 3 days. .
- Alcohol use >2 standard alcoholic drinks per day and/or alcohol or drug abuse within the past year
- Allergy or sensitivity to study supplement ingredients, study meal ingredients or allergy or sensitivity to yeasts or molds/fungi.
- Participation in a clinical research trial within 30 days prior to randomization
- Individuals who are cognitively impaired and/or who are unable to give informed consent
- Use of fish oil supplements within 10 days of randomization and during the trial
Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Digestive Enzyme #2
A proprietary blend of dietary supplement enzymes in a capsule
|
Contains dietary supplement proteases, lipases and carbohydrases
Other Names:
|
Placebo Comparator: Placebo
Capsule identical to active arm containing only microcrystalline cellulose
|
Capsule containing microcrystalline cellulose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TNF-alpha blood level change from time 0
Time Frame: 0, 45 minutes, 2 hours and 4 hours
|
Aliquots will be taken at time 0 (pre-meal), and the remainder post-meal
|
0, 45 minutes, 2 hours and 4 hours
|
IL-1beta blood level change from time 0
Time Frame: 0, 45 minutes, 2 hours and 4 hours
|
Aliquots will be taken at time 0 (pre-meal) and the remainder post-meal.
|
0, 45 minutes, 2 hours and 4 hours
|
IL-6 Blood Level change from time 0
Time Frame: 0, 45 minutes, 2 hours, 4 hours
|
Aliquots will be taken at time 0 (pre-meal), and the remainder post-meal
|
0, 45 minutes, 2 hours, 4 hours
|
hsCRP Blood Level change from time 0
Time Frame: 0, 45 minutes, 2 hours, 4 hours
|
Aliquots will be taken at time 0 (pre-meal), and the remainder post-meal
|
0, 45 minutes, 2 hours, 4 hours
|
CBC Panel change from time 0
Time Frame: 0, 4 hours
|
Aliquots will be taken at time 0 (pre-meal), and the remainder post-meal
|
0, 4 hours
|
ESR blood test change from time 0
Time Frame: 0, 4 hours
|
Aliquots will be taken at time 0 (pre-meal), and the remainder post-meal
|
0, 4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionaire: Gastrointestinal Symptoms
Time Frame: 4 hours
|
The questionaire to assess gastrointestinal symptoms associated with gastrointestinal disturbances will be administered.
|
4 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Dale Wilson, MD, KGK Synergize
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Anticipated)
December 1, 2012
Study Completion (Anticipated)
December 1, 2012
Study Registration Dates
First Submitted
November 14, 2012
First Submitted That Met QC Criteria
November 14, 2012
First Posted (Estimate)
November 20, 2012
Study Record Updates
Last Update Posted (Estimate)
November 27, 2012
Last Update Submitted That Met QC Criteria
November 26, 2012
Last Verified
November 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEC-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Prandial Inflammation Markers
-
Société des Produits Nestlé (SPN)CompletedPost-prandial GlycemiaSwitzerland
-
Cedars-Sinai Medical CenterCompletedPost-prandial Intestinal RatesUnited States
-
Unity Health TorontoCompletedPost Prandial Blood GlucoseCanada
-
BioglaneCompletedReduction of Post-prandial Glycaemic ResponseUnited Kingdom
-
St. Boniface HospitalUniversity of Manitoba; Agriculture and Agri-Food CanadaActive, not recruiting
-
Oslo Metropolitan UniversityUniversity of Oslo; Nofima; Mills DACompletedGut Microbiota | Satiety | Post Prandial Blood GlucoseNorway
-
Yale UniversityCompletedPost-Prandial Hyperglycemia | Post-Prandial HypoglycemiaUnited States
-
St Mary's University CollegeCompletedPost-prandial GlycaemiaUnited Kingdom
-
St. Boniface HospitalAgriculture and Agri-Food CanadaActive, not recruiting
-
St. Boniface HospitalUniversity of Manitoba; Agriculture and Agri-Food Canada; Saskatchewan Pulse...Completed
Clinical Trials on Digestive Enzyme #2
-
Deerland EnzymesKennesaw State UniversityRecruitingSatiety | Indigestion | Digestive Health | Protein Digestion | Carbohydrate Digestion | Fat DigestionUnited States
-
Versailles HospitalCompletedOut-of-hospital Cardiac ArrestBelgium, France
-
Assistance Publique - Hôpitaux de ParisRecruitingCephalic Duodenopancreatectomy 10 or More Years AgoFrance
-
Hôpital Edouard HerriotCompletedENDOSCOPIC CHARACTERIZATIONFrance
-
Nantes University HospitalCompleted
-
Mayo ClinicRecruitingEsophageal Cancer | Esophageal Neoplasms | Cancer of the Esophagus | Digestive System Abnormalities | Esophagus Cancer | Cancer of Esophagus | Esophagectomy | Neoplasm, Esophageal | Abnormalities, Digestive SystemUnited States
-
Xiuli ZuoNot yet recruitingFunctional Dyspepsia | Irritable Bowel Syndrome | Colorectal Neoplasms | Inflammatory Bowel Diseases | Helicobacter Pylori InfectionChina
-
AdventHealth Translational Research InstituteCompleted
-
Southwest Hospital, ChinaUnknownPancreatic Cancer | Periampullary CarcinomaChina
-
Min-Sheng General HospitalUnknown